Goldman Sachs Q2 2026 Earnings Analysis

Morgan Stanley Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: BANKS (https://betafinch.com/groups/BANKS) [https://betafinch.com/groups/BANKS)] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Morgan Stanley's second quarter 2026 results — and Jordan, this one's got some genuinely eye-popping numbers. JORDAN: It really does. But before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. ALEX: Right, let's get into it. Morgan Stanley posted record revenues of $21.3 billion for the quarter, with EPS of $3.46 — both records. First half of the year, they're at $42 billion in revenue and a 27% return on tangible common equity. That's an exceptional run. JORDAN: And it wasn't just one business carrying the load. Institutional Securities hit a record $11 billion in revenue, driven by an absolutely blowout equities quarter — $6.3 billion, up across every product and region, with Asia standing out. Investment banking revenue jumped 58% year-over-year to $2.4 billion. ALEX: That IPO market really came alive this quarter too, which fed directly into Wealth Management. They added a record $148 billion in net new assets — and CFO Sharon Yeshaya pointed out that stock plan and IPO flows made up just over half of that. Total client assets across Wealth and Investment Management now sit at $10 trillion, which CEO Ted Pick called out as a milestone the firm's been chasing for a while. JORDAN: The wealth management pre-tax margin came in at 30.5%, also a record. And there was a nice shareholder-friendly move — a 15% dividend increase to $1.15 per share, plus $1.5 billion in buybacks. Their CET1 capital ratio is at 14.8%, giving them roughly 300 basis points of excess capital cushion. ALEX: That capital question actually drove one of the more interesting exchanges in the Q&A. An analyst asked Pick point blank — why keep sitting on all this excess capital instead of deploying it more aggressively? His answer was basically: there's real client demand for that capital across every business line, and they'd rather feed the organic growth machine first. He didn't rule out bolt-on acquisitions, but said the bias is clearly toward organic investment right now. JORDAN: The moment that stood out most to me, though, was when Mike Mayo asked about the AI capital expenditure supercycle. Pick actually put real numbers on it — data center CapEx forecasts for 2026 have jumped from an initial $575 billion estimate to about $850 billion actually coming in. For 2027, projections have gone from $700 billion to $1.3 trillion. And he floated a longer-term thesis, using their research team's framework, that the AI compute buildout could eventually reach something like $10 trillion — but stressed we're only maybe 10 to 15% of the way through that cycle. ALEX: He was pretty careful to caveat that, though — called it a "known unknown" and said the numbers could shift dramatically based on chip innovation, geopolitics, supply chains. He wasn't trying to make it sound like a sure thing. JORDAN: Right, and that ties into the second big theme he flagged — the return of geopolitics as a force reshaping supply chains and capital allocation. When Gerard Cassidy asked what could make this AI-driven boom crack, Pick's answer was refreshingly candid — he referenced the dot-com bubble and the SPAC boom, and said the firm's watching closely for froth. Their mantra, as he put it, is "higher highs, but also higher lows" — meaning they want durability, not just a hot quarter. ALEX: On the wealth management side, there was also a good exchange about competition. Steven Chubak asked about smaller RIAs undercutting on price to win workplace clients. Sharon's response was essentially: scale is the moat. Corporate relationships, the breadth o This episode includes AI-generated content.

Johnson & Johnson Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: PHARMA (https://betafinch.com/groups/PHARMA) [https://betafinch.com/groups/PHARMA)], INCOME (https://betafinch.com/groups/INCOME) [https://betafinch.com/groups/INCOME)] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Johnson & Johnson's second quarter 2026 results, and Jordan, there's a lot to unpack here. JORDAN: There really is. But first, the fine print — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. ALEX: Right, so let's get into it. J&J posted $25.3 billion in quarterly sales, up 5.6% operationally. That doesn't sound huge until you realize they absorbed a 460 basis point headwind from STELARA losing patent protection to biosimilars. JORDAN: Yeah, strip out STELARA and the rest of the business grew double digits. That's the real story. Net earnings came in at $5.5 billion, diluted EPS of $2.27, and on an adjusted basis, EPS was $2.90, up nearly 5% year-over-year. And here's the kicker — they raised full-year guidance. Operational sales growth now expected at 6.5% to 7.1%, and adjusted EPS guidance moved up to $11.50-$11.65. ALEX: They're also closing in on a milestone — more than $100 billion in annual revenue for the first time in the company's 140-year history. JORDAN: Which is wild to say out loud. This is a company with 28 different products or platforms each doing over a billion dollars a year. That's not a one-hit-wonder portfolio, that's just breadth everywhere. ALEX: Let's talk oncology, because that's really where J&J flexed this quarter. DARZALEX, their multiple myeloma drug, did over $4 billion, up almost 18%. But the newer combo therapies are what caught my eye — CARVYKTI up 47.7%, TECVAYLI up 56%, TALVEY up 62.6%. JORDAN: Those growth rates on top of an already-dominant multiple myeloma franchise are pretty remarkable. And they're not resting — new data showed the TALVEY-DARZALEX combo keeping over 80% of patients progression-free at two years, with overall survival up to 89%. That's the kind of data that extends a franchise's life for years. ALEX: Then there's the newer launches — ICOTYDE in psoriasis, INLEXZO in bladder cancer, RYBREVANT in lung and now head-and-neck cancer. ICOTYDE in particular is getting a lot of attention. Over 11,000 patients started therapy, 6,000 unique prescribers, and more than half of commercial payers already covering it within 90 days. JORDAN: What's interesting is how they're positioning it alongside TREMFYA, which by the way had a monster quarter — 71% growth, its first $2 billion quarter. Instead of cannibalizing each other, management's framing ICOTYDE as the go-to first systemic treatment and TREMFYA as the first-choice biologic, especially for patients trending toward psoriatic arthritis. It's a two-pronged attack on the same disease area. ALEX: Now, MedTech was the softer spot this quarter — only 3.6% growth. Cardiovascular was the drag, mainly Abiomed's heart pump business. JORDAN: Right, and this is worth unpacking because it wasn't a demand problem. A neutral clinical trial out of the U.K. made physicians more cautious about patient selection for Impella devices, so usage slowed. Management was pretty direct about it — they called it a "behavioral" issue, not structural. They're leaning on their own much larger evidence base, over 40,000 patients studied versus the UK trial's 300, while they wait for their own PROTECT IV trial data, which won't read out until 2027. ALEX: Meanwhile, three of MedTech's four businesses — surgery, vision, and orthopedics — actually accelerated and beat expectations. So it's really one segment, heart recovery, dragging on an otherwise solid MedTech story. JORDAN: And there's real excitement building around the robotics pipeline — the OTTAVA surgical robot and MONARCH for urology are both awaiti This episode includes AI-generated content.

BlackRock Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: BANKS (https://betafinch.com/groups/BANKS) [https://betafinch.com/groups/BANKS)] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into BlackRock's second quarter 2026 numbers — and Jordan, this was a genuinely loud quarter. JORDAN: Loud is the right word. Record revenue, record operating income, record EPS, all in the same three months. ALEX: Before we get into it, a quick note. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Good, let's get into it. Revenue came in at $7.1 billion, up 31% year-over-year. Operating income jumped 39% to $2.9 billion, and EPS hit $13.91. ALEX: And the margin story is what jumped out to me. 45.9% operating margin, up 260 basis points from a year ago — that's their best level in almost five years. JORDAN: Right, and CFO Martin Small was pretty clear that 45.9% isn't a ceiling. He pointed out BlackRock ran near 47% margins back in 2021, before they even had the scale in private markets or systematic equities they have now. So there's an argument the runway keeps going. ALEX: Let's talk flows, because $192 billion of net inflows in a single quarter is enormous. That's 8% organic base fee growth for the quarter, and over the trailing twelve months they've pulled in $868 billion with 10% organic base fee growth. JORDAN: iShares ETFs led the way — $178 billion of inflows, with core equity ETFs at $85 billion and index bond ETFs setting a new record at $61 billion. Active ETFs added another $20 billion, and Larry Fink noted BlackRock has gone from the seventh-largest active ETF manager to third-largest in just three years. ALEX: The other big storyline is the HPS and GIP integration — the private markets acquisitions that closed about a year ago. Fink said the combination is already "delivering above our plans." JORDAN: The numbers back that up. HPS alone contributed about $230 million in base fees and $115 million in performance fees this quarter. And on the insurance side, Fink talked about converting general account assets — they've got roughly $800 billion of insurance assets on the platform — into higher-yielding private markets allocations. Even a 5-10% conversion rate, he said, would be a meaningful lift to average fees. ALEX: There was also that data center deal — Aligned Data Centers — described as the largest data center infrastructure transaction ever announced, bringing together their AIP, GIP, and MGX platforms. JORDAN: That ties into a theme across the whole call: hyperscalers needing balance-sheet partners to build out AI infrastructure, and BlackRock positioning itself as one of the few firms that can show up with both equity and debt capital at scale. ALEX: Let's hit tokenization for a second, because Martin Small got pretty specific here. They've filed two SEC registration statements for tokenized money market funds — one a tokenized share class on Ethereum, the other a more digitally native version with features like daily dividend reinvestment. JORDAN: And the framing was interesting — he called tokenized assets "the spear tip into an entirely new distribution channel," pointing to the roughly 5 billion digital wallets globally as a pool of potential new iShares investors. They're also already managing $60 billion in stablecoin reserves for Circle, about a quarter of that market. ALEX: On the capital return side, they bumped up guidance — now planning at least $550 million in quarterly share buybacks, higher than what they guided back in January. Combined with the dividend, they're expecting to return over $5.7 billion to shareholders this year, a 16% increase over 2025. JORDAN: One thing worth flagging for listeners: EPS growth of 15% was actually a bit lower than the 39% operating income growth This episode includes AI-generated content.

Wells Fargo Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: BANKS (https://betafinch.com/groups/BANKS) [https://betafinch.com/groups/BANKS)] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, here with Jordan, and today we're diving into Wells Fargo's second quarter 2026 results. Before we jump in — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: And Alex, this was a genuinely strong quarter for Wells Fargo. Diluted EPS hit $2, up 25% year-over-year. Revenue grew 9%. Every single operating segment posted growth in both net interest income and non-interest income. ALEX: That broad-based part is what jumps out to me. CEO Charlie Scharf made a point of saying it's not just a rising-rate-environment story — it's investments and operating discipline paying off. Headcount has now declined for 24 straight quarters, down to 197,000, while they're actually adding bankers, advisors, and traders in growth areas. JORDAN: Right, they're funding growth with efficiency savings rather than just cutting costs across the board. And the returns numbers back it up — ROTCE jumped to 17.7% this quarter, up from 15.2% a year ago. CFO Mike Santomassimo did flag that venture capital gains — $847 million in equity gains — juiced that number a bit, but even stripping that out, the underlying trend is improving. ALEX: Wells Fargo has a medium-term target of 17-18% ROTCE, and Scharf was asked repeatedly about timing on that. His answer, essentially: "we're more confident every quarter, but we're not giving you a hard date because rates and markets are unpredictable." JORDAN: Classic executive hedge, but a reasonable one. Let's talk net interest income, because that's where most of the analyst questions went. Full-year guidance stayed at $50 billion, give or take, but the composition shifted a little — loan growth is coming in better than expected, while non-interest-bearing deposits aren't growing as much as they'd hoped. ALEX: And net interest margin actually compressed again — down 4 basis points from Q1. Management's explanation is interesting: it's largely self-inflicted, in a good way. They're growing their markets business balance sheet aggressively, financing clients at lower spreads, which drags down NIM but drives higher trading revenue and deeper relationships. JORDAN: Scharf was pretty emphatic about that point — he said NIM compression "is not happening to us," it's a deliberate choice they can reverse if the payoff isn't there. Markets revenue grew 24% year-over-year, so early signs suggest it's working. They expect a bit more NIM pressure in Q3, then stabilization in Q4. ALEX: Loan and deposit growth were both double-digit — average loans up 12%, deposits up 10% — which is a big deal since Wells Fargo only got out from under the Fed's asset cap last year. They're finally playing offense after years of being constrained. JORDAN: Credit quality remained a bright spot too. Net charge-offs declined 10 basis points year-over-year to 34 basis points. Consumer delinquencies are actually coming in better than their models predict. Commercial credit is clean as well, though Scharf did flag caution around wholesale lending — data center financing, leveraged deals — where non-bank lenders are taking on more risk than Wells is willing to. ALEX: That data center commentary was one of my favorite exchanges. An analyst asked about second-derivative AI exposure, and Scharf gave a really thoughtful answer about how they underwrite different pieces of the data center supply chain differently — chip makers get paid back fast with huge margins, but other players in the chain carry much longer, riskier payback horizons. JORDAN: It showed real discipline — they're not just chasing the AI infrastructure boom blindly. On the business-line side, the Cor This episode includes AI-generated content.

JPMorgan Chase Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: BANKS (https://betafinch.com/groups/BANKS) [https://betafinch.com/groups/BANKS)] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take a dense earnings call transcript and turn it into something you can actually enjoy with your coffee. I'm Alex. JORDAN: And I'm Jordan. Today we're diving into JPMorgan Chase, ticker JPM, Q2 2026 results — and Alex, this one had a little bit of everything: blowout numbers, a leadership shakeup, and Jamie Dimon being Jamie Dimon. ALEX: Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Good, glad that's out of the way. So let's start with the headline numbers. ALEX: JPMorgan posted net income of $16.9 billion, EPS of $6.14, and a return on tangible common equity of 23%. Strip out some one-off items and revenue was actually up 15% year-over-year. JORDAN: And that growth was really broad-based — markets revenue was the biggest driver, but you also had higher asset management fees, stronger investment banking revenue, and higher deposit and loan balances. The one drag was lower rates, but honestly, that barely made a dent. ALEX: Expenses climbed too — $27.3 billion, up 15%, mostly tied to volume and revenue-related costs plus front-office hiring. Credit costs came in at $2.5 billion. And here's a nice surprise for investors: the board is bumping the quarterly dividend up to $1.65 a share starting next quarter. JORDAN: Let's talk about the business lines, because two of them really stood out. The CIB — that's the Corporate and Investment Bank — had a monster quarter. Revenue up 27% year-over-year, investment banking fees up 30%, with double-digit growth across the board. ALEX: And equities trading? Up 86% year-over-year. Eighty-six percent, Jordan. JORDAN: That's the kind of number that makes you sit up. CFO Jeremy Barnum was pretty candid on the call though — he said this level of equities strength is "a little bit hard to imagine being repeated." So management itself is tapping the brakes on extrapolating this quarter forward. ALEX: Right, and same with investment banking — some of that came from large deals getting pulled forward and a couple of high-profile IPOs. But he also said the pipeline remains "quite robust," and there's this interesting dynamic where the buzz around big deals seems to be generating even more activity. JORDAN: Meanwhile, on the asset and wealth management side, AUM hit $5.1 trillion, up 18%, with $50 billion in long-term net inflows. And in consumer banking, they added over 500,000 net new checking accounts this quarter. That's a franchise that's just quietly compounding. ALEX: Let's get into the bigger story of the call, though — the leadership news. JPMorgan just elevated Doug and Troy to co-presidents, and long-time consumer banking head Marianne Lake is retiring as a result. JORDAN: This dominated the Q&A. Analysts kept probing Jamie Dimon about succession, and he was pretty firm that the timetable for his own tenure "hasn't changed" — still talking in terms of a few years, plus or minus, with the board ultimately deciding. ALEX: One exchange I loved — Mike Mayo basically said, half-joking, "you've now got an FX trader running the consumer bank," referring to Troy. Barnum jumped in to correct him: Troy was actually an options trader, not FX. Small detail, but it got a laugh. JORDAN: Dimon's broader point was that he wants leaders who've operated across the whole company, not just people who came up through investment banking. He was pretty explicit that leaders who only understand trading or dealmaking can end up neglecting the rest of the franchise. ALEX: Let's talk guidance, because they raised it meaningfully. Full-year NII outlook ex-Markets moved up This episode includes AI-generated content.